May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Gatifloxacin 0.3% compared to Ciprofloxacin 0.3% to prevent Mycobacterial Keratitis in an animal model
Author Affiliations & Notes
  • H.P. Sandoval
    Ophthalmology/Magill Res Ctr, Storm Eye Institute, Charleston, SC
  • L.E. Fernandez de Castro
    Ophthalmology/Magill Res Ctr, Storm Eye Institute, Charleston, SC
  • O. Al Sarraf
    Ophthalmology/Magill Res Ctr, Storm Eye Institute, Charleston, SC
  • L.L. Steed
    Ophthalmology/Magill Res Ctr, Storm Eye Institute, Charleston, SC
  • S.J. Brown
    Ophthalmology/Magill Res Ctr, Storm Eye Institute, Charleston, SC
  • D.T. Vroman
    Ophthalmology/Magill Res Ctr, Storm Eye Institute, Charleston, SC
  • K.D. Solomon
    Ophthalmology/Magill Res Ctr, Storm Eye Institute, Charleston, SC
  • Footnotes
    Commercial Relationships  H.P. Sandoval, Allergan F; L.E. Fernandez de Castro, None; O. Al Sarraf, None; L.L. Steed, None; S.J. Brown, None; D.T. Vroman, Allergan F; K.D. Solomon, Allergan F.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 4905. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H.P. Sandoval, L.E. Fernandez de Castro, O. Al Sarraf, L.L. Steed, S.J. Brown, D.T. Vroman, K.D. Solomon; Gatifloxacin 0.3% compared to Ciprofloxacin 0.3% to prevent Mycobacterial Keratitis in an animal model . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4905.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To compare the efficacy of gatifloxacin ophthalmic solution 0.3% to ciprofloxacin ophthalmic solution 0.3% in preventing mycobacterial keratitis after creating a flap in an animal model. Methods: In 25 eyes of 15 New Zealand rabbits a corneal flap was created, lifted, and the interface and stroma inoculated with M. chelonae. Eyes were randomized to one of three groups, as follows: 0.3% gatifloxacin, 0.3% ciprofloxacin or control. Treatment was initiated immediately after the surgery and applied 4 times a day for one week, then discontinued. After the final clinical examination at day 21, some globes were enucleated, and corneas harvested under sterilized conditions to be processed for microbiology, histopathologic analysis by standard light microscopy, and scanning electronic microscopy. Results: At day 21, 100% of controls, 60% of the ciprofloxacin group and 10% of gatifloxacin had infection. (P < .05). Conclusions: Gatifloxacin demonstrated an improved activity towards atypical mycobacteria keratitis prevention compared to ciprofloxacin.

Keywords: antibiotics/antifungals/antiparasitics • keratitis • bacterial disease 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×